**Effects of neurofeedback versus methylphenidate for the treatment of ADHD:**

**protocol for a systematic review and meta-analysis of head-to-head trials**

Lixia Yan PhDa,b\*, Junhua Zhang PhDb, Yang Yuan MDc, Samuele Cortese MD,PhD d,e,f,g,h\*\*

a School of Education, Soochow University, 215123,Soochow, China

b School of Education, Jiangsu Key Laboratory for Big Data of Psychology and Cognitive Science, Yancheng Teachers University,224002, Yancheng, China

c Department of Paediatrics, Yancheng traditional Chinese medicine hospital, Yancheng, China

d Center for Innovation in Mental Health, Academic Unit of Psychology, University of Southampton, UK, SO17 1BJ

e Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, UK, SO17 1BJ

f Solent NHS Trust, Southampton, UK, SO19 8BR

g New York University Child Study Center, New York, NY, USA, 10016

h Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK, NG7 2UH

**Address correspondence to:** Junhua Zhang, Ph.D. School of Education, 50 Kaifang RoadYancheng Teachers University, Yancheng, Jiangsu 224002,P.R.China E-mail: junhuazh2003@163.com

**Competing interests:** Dr.Junhua Zhang has received financial support from the projects of philosophy and social science of Jiangsu Province (14JYD007) and from Jiangsu Overseas Research & Training Program for University Prominent Young & Middle-Aged Teachers and Presidents([2017]3523). Sponsors will not participate in this study. Samuele Cortese, LixiaYan and Yang Yuan have no competing interests.

**Funding:** This study was supported by the projects of philosophy and social science of Jiangsu Province (14JYD007) and from Jiangsu Overseas Research & Training Program for University Prominent Young & Middle-Aged Teachers and Presidents ([2017]3523).

**ABSTRACT**

**Introduction:** Attention-Deficit/Hyperactivity Disorder (ADHD) is developmental disorder characterized by inattention and/or hyperactivity/impulsivity. Psychostimulants, including methylphenidate (MPH), are recommended as a first-line pharmacological intervention, while neurofeedback (NF) has been proposed as a non-pharmacological option. The comparative effects of MPH and NF need further exploration. We will conduct a systematic review and meta-analysis of head-to-head randomised controlled trials (RCTs) comparing the efficacy and/or tolerability of MPH and NF in children/adolescents and adults with ADHD.

**Method and Analysis:** We will include published as well as unpublished data. Two investigators will independently search PubMed, OVID, ERIC, Web of Science, ClinialTrials.gov and a set of Chinese databases, including CNKI, CQVIP and WanFang for head-to-head RCTs comparing MPH and NF. Experts will be contacted for unpublished data. The primary outcome will be the efficacy on ADHD core symptoms, measured by the change in the severity of ADHD symptoms, from baseline to endpoint and, if available, at follow-up (at any available time point). Secondary outcomes will be: 1) dropouts for any reasons; 2) efficacy on neuropsychological measures (working memory, inattention, and inhibition). We will conduct subgroup analyses to assess the impact of the following variables: (1) age; (2) type of NF; (3) language of publication; (4) comorbidities. Additionally, we will carry out meta-regression analyses to investigate the effect of sponsorship, year of publication, duration of intervention, and age of participants. Sensitivity analyses will be conducted to test the robustness of the findings. Risk of bias of individual studies will be assessed using the Cochrane risk of bias tool. Analyses will be performed using Comprehensive Meta-Analysis Software (CMA).

**Ethics and Dissemination:** No ethical issues are foreseen. Results from this study will be published in a peer-reviewed journal and presented at relevant national and international conferences.

**Trials registration number: PROSPERO** [CRD42018090256](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018090256)

**Abbreviations:** ADHD = Attention-Deficit/Hyperactivity Disorder, CMA= Comprehensive Meta-Analysis Software, CNKI = China National Knowledge Infrastructure, DSM = Diagnostic and Statistical Manual of Mental Disorders, HD = Hyperkinetic Disorder, ICD = International Classification of Diseases, IVA/CPT =Integrated Visual and Auditory Continuous Performance Test, M = mean, MPH = methylphenidate, N = number of subjects, NF=neurofeedback, NOS = Newcastle–Ottawa scale, OR = odds ratios, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PROSPERO = Prospective Register of Systematic Reviews, RCT=randomised controlled trial, ROB= risk of bias tool, SD= standard deviation, SMD = standardized mean difference, TOVA= Test of Variables of Attention, VSWM =the visual spatial working memory

**Keywords:** Neurofeedback; Methylphenidate; ADHD; systematic review; meta-analysis

**1. Introduction**

Attention-Deficit /Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders, 1-3affecting about 5% of school-aged children and around 2.5% of adults worldwide. 4,5ADHD not only has an important impact on virtually every aspect of a individual’s physical and mental health, daily functioning, and academic/occupational performance in the short and long run, but also entails a huge economic burden to patients, families, and broader society. 6-8 Currently, several pharmacological and non-pharmacological options, such as behavioral interventions /parenting skills, dietetic changes and cognitive training, have been proposed for the treatment of ADHD. 9-11 Psychostimulants, including methylphenidate (MPH), are recommended as a first-line pharmacological option in several guidelines for the treatment of ADHD. 12-17 MPH, the most commonly used psychostimulant in many countries, inhibits the reuptake of dopamine and norepinephrine, increasing dopaminergic and noradrenergic activity in the prefrontal cortex which may contribute its efficacy and effectiveness in ADHD. 18,19 Despite evidence from short-term randomised controlled trials (RCT) pointing to large effect size (among the largest not only in psychiatry but also in general medicine) for MPH( teacher-reported ADHD symptom ratings (SMD -0.83;95%CI:-0.96,-0.70),general behaviour (SMD -0.68;95%CI:-0.78,-0.60),and quality of life (SMD 0.61;95%CI:0.48,0.80) ), 20 there are concerns over its tolerability and mixed evidence on its long-term effects.18 Storebo et al. stated that MPH may improve symptoms of ADHD but is associated with a relatively high risk of non-serious adverse events.21,22

Therefore, alternative non-pharmacological options directly targeting the pathophysiology of ADHD are currently being actively investigated. Among these, neurofeedback (NF) has been proposed by a number of research groups as an effective and safe option for ADHD.23,24 NF is a process of operant conditioning which aims at improving self-regulation of brain activity. 25,26 Meta-analytic evidence on the efficacy of NF for ADHD is currently mixed. Arns et al. 2014 pooled 15 studies (including 476 subjects from 11 prospective controlled studies and 718 subjects from 4 pre-post-test design studies) and concluded that NF treatment for ADHD can be considered "efficacious and specific", with a large ES ( 0.8097 and 0.6862 respectively) for inattention and impulsivity and a medium ES (0.3962) for hyperactivity. 27 By contrast, Cortese and colleagues of the European ADHD Guidelines Group (EAGG), 2016,after pooling 13 RCTs (including 520 participants with ADHD), found that, whilst ratings from unblinded assessors show significant effects of NF in reducing ADHD core symptoms, ratings from probably blinded assessors fail to support NF as an effective treatment for ADHD core symptoms. 28 Overall, we are not aware of any evidence suggesting that NF outperforms placebo-NF for ADHD.

Evidence on the comparative efficacy/effectiveness and tolerability of MPH and NF needs further investigation. Catala-Lopez et al. 2017 did a comprehensive network meta-analysis including, among other treatments, MPH and NF. MPH emerged as more efficacious than NF on ADHD symptoms and global functioning. 29 However, the meta-analysis by Catala-Lopez et al. 2017 did not focused on the effects of MPH and NF on subdomains of ADHD separately (i.e., inattention and hyperactivity-impulsivity). This is of relevance given that previous studies have shown that inattention and hyperactivity/ impulsivity symptoms may have different degrees of sensitivity to different treatments. 27 Additionally, Catala-Lopez et al. 2017 chose to use a dichotomous outcome (i.e., proportion of patients who displayed improvements in the symptoms of ADHD or global functioning on standardized rating scales), which may be less informative compared to continuous outcomes. 30

Furthermore, when considering the comparison between MPH and NF, a key aspect relates to sustained effects. A meta-analysis by Van Doren et al. 2018 focused on sustained effects (defined by these authors as follow-up at 2–12 months) of NF in ADHD. They found that, compared to non-active control treatments, NF had significantly more durable treatment effects for at least 6 months following treatment, although the authors concluded that more studies are needed for a properly powered comparison of follow-up effects between NF and active treatments. 31 Indeed, this meta-analysis could not inform on the sustained effect of NF and MPH directly because it combined MPH with other active treatments including attention training, cognitive training, physical activity training, and self-management.

Finally, another aspect that deserves further investigation relates to the comparative efficacy of MPH and NF on neuropsychological measures, such as working memory or sustained attention. This is of relevance because executive dysfunctions, albeit far from being universal in ADHD, affect a sizable portion of individuals with ADHD and impact on their academic and global functioning. 32

Therefore, a number of questions still need to be answered in relation to the comparative efficacy and tolerability of MPH and NF.

**2. Objectives**

Our study aimed to fill these gaps by means of a systematic review and meta-analysis of head-to-head RCTs comparing the effects (at trial end point and, if available, at follow-up) in terms of efficacy of MPH and NF on separate ADHD core symptoms (Inattention and Hyperactivity/Impulsivity), using continuous measures as outcome. We will also explore the feasibility of assessing the comparative effects on neuropsychological variables. We also will assess the comparative tolerability of MPH and NF.

**3.METHODS**

Methods for this systematic review/meta-analysis have been developed according to recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 33

**3.1Eligibility Criteria**

**3.1.1Population**

Individuals [children/adolescents (< 18 years) and or adults (≥ 18 years)] with a categorical diagnosis of ADHD according to the DSM (III, III-R, IV, IV-TR or 5) or Hyperkinetic Disorder (HYD) as per the ICD-10 or previous ICD versions or above cut point on any validated ADHD measure. 34,35

**3.1.2Intervention(s)**

We will include trials comparing NF and MPH. Both fixed-dose and flexible-dose designs (in relation to the MPH regime) will be allowed. Studies assessing the efficacy of multimodal treatments including the combination of NF plus other treatments will be excluded.

**3.1.3Comparator(s)/control**

Studies including a non-active comparator will be retained if they include at least two other active arms, i.e., MPH and NF.

**3.1.4Types of outcome(s)**

The primary outcome will be the efficacy (as a continuous outcome) on the severity of ADHD core symptoms (at the end of the study and, if available, at follow-up, filled out by parents, teachers, patients or clinician(s). We will perform an analysis focusing on the total ADHD score, i.e. inattentive plus hyperactive/impulsive symptoms, and another analysis focusing on ADHD subdomains, i.e., analysing separately inattention and hyperactivity/impulsivity. Validated ADHD rating scales that we will consider eligible for the measurement of the outcomes are reported in Table 1. 36 As in previous studies, 37 we will conduct separate analyses for measures rated by 1) clinicians, 2) parents, 3) teachers, and 4) patients (self). Secondary outcomes will be the number of dropouts for any reasons at the end of the intervention (and, if available, at follow-up) and neuropsychological laboratory-based measures of working memory (e.g., The visual spatial working memory task (VSWM), 38 attention (e.g., Test of Variables of Attention (TOVA) , 39,40Attention Endurance Test (d2) 41), and inhibition (e.g., Integrated Visual and Auditory Continuous Performance Test (IVA/CPT). 42).

Timing: the primary analysis will focus on endpoint- baseline changes; secondary analyses will focus on data, when available, at a follow-up (time point closest to 12 months after treatment as in Van Doren et al. 2018 and other studies. 31,43, or longer follow-up, if available).

**3.1.5 Types of Study**

RCTs will be included, regardless the level of blinding. Parallel-group RCTs , crossover trials and, if available, cluster trials will be considered . For cross-over studies, to due to concerns on possible “carry-over” effects, 44 we will use data from the pre-crossover phase, whenever this is reported in the study report. When data for the pre-cross over phase are not reported, we will contact study authors to obtain them.

**3.2Search strategy**

We will include published and unpublished studies pertinent to our criteria. An electronic literature search will be conducted independently by two authors. The following electronic databases will be searched with no language, date, and type of document restrictions: PubMed, OVID, ERIC and Web of Science (including Science Citation Index Expanded (SCI-EXPANDED). Chinese databases, including China National Knowledge Infrastructure (CNKI),CQVIP and WanFang data, will also be searched with the translated searching strategy. We will also search Clincaltrials.gov, clinicaltrialsregister.eu and osf.io for additional reports not published in peer-reviewed journals.

The search terms/syntax in PubMed  will be as follows:

(adhd OR adhd OR attention deficit disorder with hyperactivity OR minimal brain disorder OR syndrome hyperkinetic OR hyperkinetic syndrome OR hyperactivity disorder OR hyperactive child syndrome OR childhood hyperkinetic syndrome OR attention deficit hyperactivity disorders OR attention deficit hyperactivity disorder OR adhd attention deficit hyperactivity disorder OR addh OR overactive child syndrome OR attention deficit hyperkinetic disorder OR hyperkinetic disorder OR attention deficit disorder hyperactivity OR attention deficit disorder hyperactivity OR child attention deficit disorder OR hyperkinetic syndromes OR syndromes hyperkinetic OR hyperkinetic syndrome childhood) AND (neurofeedback OR neuro feedback OR "EEG biofeedback" OR neuro therapy OR neurotherapy OR SCP OR "slow cortical potentials") AND (Methylphenidate\* OR methylphenidate\* OR Ritalin OR ritalin)

The search strategy/syntax will be adapted for each database. The references of all selected studies will be hand searched for other published reports and citations of unpublished studies. Finally, we will contact experts in the field to query about any completed study not yet published.

**3.3Data extraction**

Studies identified through electronic and manual searches will be listed with citation, titles, and abstracts in EndNote; duplicates will be excluded using the EndNote function “remove duplicates”. The eligibility for inclusion process will be conducted in two separate stages:

1. Two authors will independently screen title and abstracts of all non-duplicated papers and will exclude those not pertinent to the criterion. A final list will be agreed with discrepancies resolved by consensus between the two authors. When consensus is not reached, a third senior author will act as arbitrator. If any doubt about inclusion exists, the article will proceed to the next stage.

2. The full-text version of the articles passing stage 1 screening will be downloaded and assessed for eligibility by two authors, independently. We will provide a complete list of articles excluded at the full-text screening stage, with reasons for exclusion. Discrepancies will be resolved by consensus between the two authors and, if needed, a third senior author will act as arbitrator. Data from multiple reports of the same study will be linked together. Where required, we will contact the corresponding author to inquire about study eligibility.

One reviewer will input outcome data from studies included in previous systematic reviews into Excel. This will be independently cross-checked by another reviewer. The following data will be collected from each included study:

• Study details: First author/study ID, year(s) of study or publication, location (country or continent), setting, diagnostic criteria, funding/sponsor (industry or academic);

• Participants details, including number, gender distribution, mean and range of age, presence, and type of co-morbid (neuro) psychiatric conditions, mean (and SD) IQ, numbers in each group, and a number of dropouts for side effects in both groups.

• Interventions details, including mean and maximum doses of MPH, type of NF, the duration of interventions, and whether forced dose or optimized treatment with MPH; time(s) of outcome measurement;

• Outcomes: mean, SD or percentage in both groups at pre-test, post-test, and follow-up (any time point reported).

• Effect size, statistical power, and the original researcher’ hypothesis for each study.

• Information as to whether participants in the NF studies learn to regulate the feedback.

**3.4 Risk of bias (quality) assessment**

Risk of bias will be assessed for each included study using the Cochrane Collaboration risk of bias tool (ROB), as a reference. 45 The risk of bias domains include selection bias, performance bias, detection bias, attrition bias, and other bias. Two independent review authors will assess the risk of bias in selected studies. The degree of agreement between the two independent raters will be reported. Any disagreement will be resolved through discussion and in consultation with the principal investigators. Where necessary (i.e., unclear information for the published report), the authors of the studies will be contacted for further information. As in Cortese et al., the overall rating of risk of bias for each study will be the lowest rating for any of the criteria (e.g., if any domain is scored high risk of bias, the study will be considered high risk of bias). 46

**3.5 Data synthesis**

Meta-analyses will be performed by means of Comprehensive Meta-Analysis Software (CMA) (http:// [www.meta-analysis.com/index.php)](http://www.meta-analysis.com/index.php)) using the option “standardized by post score SD”. Additionally, we will use the appropriate function in CMA, to combine outcomes within study from the same subjects (https://www.meta-analysis.com/downloads/Multiple%20outcomes.pdf).Heterogeneity will be assessed and measured with Cochran's Q and I2 statistics, which estimates the percentage of variation among effect sizes that can be attributed to heterogeneity. 47 I2 > 0 indicates that the degree of heterogeneity is greater than would be expected by chance. Clinically significant values will be indicated by SMD > 0.4 .48

**3.6 Subgroup and meta-regression analyses**

We will explore the feasibility of conducting subgroup analyses to assess the impact of the following variables: (1) age of population; (2) the language in which studies were published; (3) comorbidities. Additionally we will carry out meta-regression analyses in order to investigate the effect of sponsorship, year of publication, duration of intervention, age of participants.

**3.7 Publication bias**

Publication bias will be assessed via funnel plots and Eggers’ test. 49

**3.8 Sensitivity analyses**

We will perform the following sensitivity analyses by: (1) removing studies rated at overall high risk of bias;(2) excluding studies with small sample size trials (at least 30 children per arm);(3) excluding studies where the diagnosis was not made according to standardised DSM/ICD criteria; (4) excluding unpublished data; (5) removing studies on non standard NF (i.e TBR, SMR and SCP) as per Arns et al. 2014. 26 We will also explore the feasibility of conducting sensitivity analyses by :(1) excluding studies not using the Conners’ scale; (2) excluding studies without teachers’ rating.

**3.9 Ethics and dissemination**

This systematic review and meta-analysis will not undertake any primary data collection, so no ethical approval is required. The findings of this study will be published in a peer-reviewed journal.

**4. Strengths and limitations of this study**

This is a comprehensive meta-analysis of head-to-head trials of methylphenidate (MPH) vs neurofeedback using published and unpublished data. ADHD sub-domains as well as on neuropsychological measures will be considered separately. Comparative effects of MPH and NF on ADHD will be assessed not only at study endpoint but also at follow-up. A possible limitation is the inclusion of different rating scales to assess the core symptoms of ADHD. However, we will select only validated scales that measure exclusively the same triad of symptoms, i.e., inattention, hyperactivity, and impulsivity.

**Author Contributions**

Lixia Yan and Junhua Zhang conceived the study and drafted the protocol. Samuele Cortese supervised the study design and edited the first draft of the protocol. Samuele Cortese and Junhua Zhang designed the search strategy. Lixia Yan and Yang Yuan reviewed and commented on the protocol in PROSPERO. All authors (Junhua Zhang, Lixia Yan, Yang Yuan, Samuele Cortese) contributed to the development of inclusion and exclusion criteria. All authors ((Junhua Zhang, Lixia Yan, Yang Yuan, Samuele Cortese) read, contributed, and approved the final manuscript.

Conceptualization: Lixia Yan, Junhua Zhang, Samuele Cortese.

Investigation: Lixia Yan, Junhua Zhang, Yang,Yuan.

Methodology: Lixia Yan, Junhua Zhang, Samuele Cortese.

Project administration: Lixia Yan, Junhua Zhang, Yang,Yuan.

Writing, review & editing: Junhua Zhang, Samuele Cortese.

**References**

1. Barnett R. Attention deficit hyperactivity disorder. *Lancet (London, England).* 2016;387(10020):737.

2. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. *Eur Child Adolesc Psychiatry.* 2010;19(2):83-105.

3. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. *The Journal of clinical psychiatry.* 2006;67(4):524-540.

4. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. *Journal of child psychology and psychiatry, and allied disciplines.* 2015;56(3):345-365.

5. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *The British journal of psychiatry : the journal of mental science.* 2009;194(3):204-211.

6. Cunill R, Castells X. [Attention deficit hyperactivity disorder]. *Med Clin (Barc).* 2015;144(8):370-375.

7. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. *Current medical research and opinion.* 2005;21(2):195-206.

8. Connolly JJ, Glessner JT, Elia J, Hakonarson H. ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder. *Ther Innov Regul Sci.* 2015;49(5):632-642.

9. Sonuga-Barke EJS, Brandeis D, Cortese S, et al. Nonpharmacological Interventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological Treatments. *American Journal of Psychiatry.* 2013;170(3):275-289.

10. Cortese S, Rosello-Miranda R. Treatments for children and adolescents with attention deficit hyperactivity disorder: what is the evidence base to date? *Revista De Neurologia.* 2017;64:S3-S7.

11. Richardson M, Moore DA, Gwernan-Jones R, et al. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research. *Health technology assessment (Winchester, England).* 2015;19(45):1-470.

12. NICE. Attention defificit hyperactivity disorder:diagnosis and management. In. *National Clinical Practice Guideline Number 87*. 14 March 2018 ed. London: National Institute for Clinical Excellence; 2018.

13. Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. *Journal of psychopharmacology (Oxford, England).* 2014;28(3):179-203.

14. Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics.* 2011;128(5):1007-1022.

15. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. *BMC psychiatry.* 2010;10:67.

16. Pliszka S, Issues AWGoQ. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry.* 2007;46(7):894-921.

17. CADDRA. Canadian ADHD Practice Guidelines. https://www.caddra.ca/canadian-adhd-practice-guidelines/. Accessed May 15th, 2018.

18. Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. *Mol Psychiatry.* 2017.

19. Reddy DS. Current pharmacotherapy of attention deficit hyperactivity disorder. *Drugs of today (Barcelona, Spain : 1998).* 2013;49(10):647-665.

20. Banaschewski T, Buitelaar J, Chui CS, et al. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater. *Evid Based Ment Health.* 2016;19(4):97-99.

21. Storebo OJ, Krogh HB, Ramstad E, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. *BMJ (Clinical research ed).* 2015;351:h5203.

22. Storebo OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. *The Cochrane database of systematic reviews.* 2018;5:CD012069.

23. Duric NS, Assmus J, Elgen IB. Self-reported efficacy of neurofeedback treatment in a clinical randomized controlled study of ADHD children and adolescents. *Neuropsychiatric disease and treatment.* 2014;10:1645-1654.

24. Flisiak-Antonijczuk H, Adamowska S, Chladzinska-Kiejna S, Kalinowski R, Adamowski T. Treatment of ADHD: comparison of EEG-biofeedback and methylphenidate. *Archives of Psychiatry and Psychotherapy.* 2015;17(4):31-38.

25. Strehl U. What learning theories can teach us in designing neurofeedback treatments. *Frontiers in human neuroscience.* 2014;8:894.

26. Arns M, Heinrich H, Strehl U. Evaluation of neurofeedback in ADHD: the long and winding road. *Biological psychology.* 2014;95:108-115.

27. Arns M, de Ridder S, Strehl U, Breteler M, Coenen A. Efficacy of Neurofeedback Treatment in ADHD: the Effects on Inattention, Impulsivity and Hyperactivity: a Meta-Analysis. *Clinical Eeg and Neuroscience.* 2009;40(3):180-189.

28. Cortese S, Ferrin M, Brandeis D, et al. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. *Journal of the American Academy of Child and Adolescent Psychiatry.* 2016;55(6):444-455.

29. Catala-Lopez F, Hutton B, Nunez-Beltran A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. *PloS one.* 2017;12(7):e0180355.

30. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ (Clinical research ed).* 2006;332(7549):1080.

31. Van Doren J, Arns M, Heinrich H, Vollebregt MA, Strehl U, S KL. Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. *European child & adolescent psychiatry.* 2018.

32. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. *Biological psychiatry.* 2005;57(11):1336-1346.

33. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Bmj-Brit Med J.* 2009;339.

34. Cortese S. Are concerns about DSM-5 ADHD criteria supported by empirical evidence? *Bmj-Brit Med J.* 2013;347.

35. Doernberg E, Hollander E. Neurodevelopmental Disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11. *Cns Spectrums.* 2016;21(4):295-299.

36. ML W. Vanderbilt ADHD Teacher Rating Scale (VADTRS) and the Vanderbilt ADHD Parent Rating Scale (VADPRS). 2003. www.nichq.org.

37. Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. *The American journal of psychiatry.* 2013;170(3):275-289.

38. Westerberg H, Hirvikoski T, Forssberg H, Klingberg T. Visuo-spatial working memory span: a sensitive measure of cognitive deficits in children with ADHD. *Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence.* 2004;10(3):155-161.

39. Greenberg LM. An Objective-Measure of Methylphenidate Response - Clinical Use of the Mca. *Psychopharmacol Bull.* 1987;23(2):279-282.

40. Fuchs T, Birbaumer N, Lutzenberger W, Gruzelier JH, Kaiser J. Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: a comparison with methylphenidate. *Applied psychophysiology and biofeedback.* 2003;28(1):1-12.

41. Brickenkamp R. *Test d2, Aufmerksamkeits-Belastungs-Test* G¨ottingen: Hogrefe; 1994.

42. Moreno-Garcia I, Meneres-Sancho S, Camacho-Vara de Rey C, Servera M. A Randomized Controlled Trial to Examine the Posttreatment Efficacy of Neurofeedback, Behavior Therapy, and Pharmacology on ADHD Measures. *Journal of attention disorders.* 2017:1087054717693371-1087054717693371.

43. Steiner NJ, Frenette EC, Rene KM, Brennan RT, Perrin EC. In-School Neurofeedback Training for ADHD: Sustained Improvements From a Randomized Control Trial. *Pediatrics.* 2014;133(3):483-492.

44. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. *Stat Med.* 2002;21(15):2161-2173.

45. JP H, S G. *Cochrane Handbook for Systematic Reviews of Interventions.* Chichester: John Wiley and Sons; 2011.

46. Cortese S, Adamo N, Mohr-Jensen C, et al. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. *BMJ open.* 2017;7(1):e013967.

47. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. *Introduction to meta-analysis* New Jersey: John Wiley & Sons, Ltd; 2009.

48. Citrome L. Quantifying clinical relevance. *Innovations in clinical neuroscience.* 2014;11(5-6):26-30.

49. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed).* 1997;315(7109):629-634.